MEC Plus Full List ViewBy pinki@katapult.biz / February 16, 2025 MEC Plus Events — 2025 MaTOS Breast 2025 MaTOS GU 2025 MCM 2025 PRIMO 2025 South Florida GI Cancer Symposium 2025 Winter Cancer Symposium (WCS) 2024 Advances in Oncology Conference 2024 Best of WCLC San Francisco 2024 California Cancer Consortium Conference (CCC) 2024 MaTOS Lungs 2024 MCM 2024 MLS Cleveland 2024 MLS Irvine 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PACC Miami 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 Updates in Cancer Therapies 2024 WCS Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignant Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Oral Cancer Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Type of Media — Video Document Audio Author / Speaker Title Search Entries: « 1 … 37 38 39 40 41 … 100 » How to Navigate Through Relapsed-Refractory Myeloma Patient Jonathan Kaufman, MD View Video How to Combine RT and Immunotherapy Without Compromising Anti-tumor Effect? Percy Lee, MD View Video How to Choose the Best 1L in a Newly Diagnosed Multiple Myeloma Patient? Saad Usmani, MD, MBA, FACP View Video GIST and Soft Tissue Sarcomas: Focus on Personalized Medicine Pasquale W. Benedetto, MD View Video Geriatric Oncology: Pitfalls to Deliver Good Care in the Elderly Cancer Patient Tom Reske, MD, PhD, FACP, CMD, AGSF View Video Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine Nakhle Saba, MD View Video Esophageal, Gastric and GE Junction Tumors: What’s New in 2023? Mike Cusnir, MD View Video EGFRex20ins, METex14 and RET in NSCLC Mark Socinski, MD View Video Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold? Mark Pegram, MD View Video De Novo Acute Myeloid Leukemia Richard Stone, MD View Video ctDNA in Lung Cancer: Current State and Future Perspectives Bruna Pellini, MD View Video ctDNA in Adjuvant and Metastatic Therapy for GI Cancers: Prime Time? Olatunji B. Alese, MD, FWACS View Video Cancer Disparity from Different Angles: How to Tackle It? John Carpten, PhD View Video Bringing Personalized Medicine to Colorectal Cancers Michael J. Overman, BS, MD, MHA View Video Artificial Intelligence in Oncology Care Kristina Rua, MSN, RN, OCN, ONN-CG View Video ALK: Choosing 1L & Mechanism of Resistance Ibiayi Dagogo-Jack, MD View Video ADC in NSCLC: TROP2 and HER3 in NSCLC Hossein Borghaei, MD View Video ADC in NSCLC: CEACAM5 and Teliso-V Julia Rotow, MD View Video HER2 Targeted Therapies: Recent Advances Helen Chew, MD, FACP View PDF New Biomarkers in Breast Cancer Tanya Gupta, MD View PDF Hormone Therapy in Breast Cancer: New Directions Mili Arora, MD View PDF ADCs in Cancer Mille Das, MD View PDF PIK3CA/AKT/mTOR Jacob Thomas, MD View PDF DDR and DNA-Repair Pathways and Targets Mamta Parikh, MD, MS View PDF BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology Tycel Phillips, MD View PDF Contemporary Management of Urothelial Cancer Abhishek Tripathi, MD View PDF Renal Cell Cancer: Recent Advances Suchi Gulati, MD, MS, FACP View PDF Castration Resistant Prostate Cancer: What is the optimal treatment? Sandy Srinivas, MD View PDF State of the Art: Hormone-sensitive Prostate Cancer Sarmad Sadeghi, MD, PhD View PDF Lymphoma: State of the Art Alex Herrera, MD View PDF ← Previous View We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
